EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

MK2 promotes p16 negative head and neck cancer migration, invasion, and metastasis

Deri Morgan, Dakota Dd Okwuone, Kiersten L Berggren, Levi Arnold, Alyssa Schmidt, Colby Spiess, Hannah Smith, Ravi Yada, Nathan Hendrikse, Rashna Madan, Devin Shrock, Chris Lominska und 10 weitere

Cancer Letters · 2025-07 · 622 · 217690

DOI: 10.1016/j.canlet.2025.217690 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Cancer Letters, 2025-07. Verfasst von Deri Morgan und 21 weiteren Autor:innen. Beteiligte Einrichtung: Department of Radiation Oncology, University of Kansas Medical Center, Kansas City, KS, USA. Hauptthemen laut MEDLINE: Cell Movement, Head and Neck Neoplasms, Intracellular Signaling Peptides and Proteins, Protein Serine-Threonine Kinases. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 42 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NIGMS NIH HHS, NCI NIH HHS, NIBIB NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

For patients with locally advanced, p16-negative head and neck squamous cell carcinoma (HNSCC), overall survival remains poor due to primary locoregional failure and distant metastasis following curative therapy. We aimed to understand how MAPKAPK2 (MK2) regulates HNSCC tumor cell migration and invasion, important first steps in cancer metastases. The TCGA database and HNSCC tissue microarrays were used to show that MK2 expression was associated with more advanced cancers and faster cancer recurrence rates. We observed that silencing of tumor MK2 in human cell lines (shRNA) caused a significant reduction in tumor cell migration-invasion in a complex HNSCC microphysiologic system used to recapitulate the tumor microenvironment. Murine cells (Ly2) with MK2 silenced (CRISPR-Cas9) also demonstrated reduced migration and invasion using 2D and 3D monoculture cell migration-invasions assays. Ly2 cells are orthotopic p16-negative murine metastatic cells that spontaneously metastasize, and we observed that MK2 inhibition via genetic (Cas9/CRISPR) or pharmacologic (PF-3644022) methods led to a significant reduction in the number of circulating tumor cells, fewer lymph node and lung metastases, and MK2 inhibited mice showed improved overall survival. Our findings suggest that HNSCC MK2 regulates tumor cell migration-invasion and may be a promising therapeutic target to reduce metastases.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Cell MovementHead and Neck NeoplasmsIntracellular Signaling Peptides and ProteinsProtein Serine-Threonine KinasesSquamous Cell Carcinoma of Head and NeckCyclin-Dependent Kinase Inhibitor p16HumansAnimalsMiceNeoplasm InvasivenessCell Line, TumorTumor MicroenvironmentGene Expression Regulation, NeoplasticNeoplasm MetastasisFemaleMaleMAP-Kinase-Activated Kinase 2

Substanzen

Intracellular Signaling Peptides and ProteinsProtein Serine-Threonine KinasesCyclin-Dependent Kinase Inhibitor p16MAP-Kinase-Activated Kinase 2CDKN2A protein, human

Autor:innen und Institutionen

  • Department of Radiation Oncology, University of Kansas Medical Center, Kansas City, KS, USA.
  • The University of New Mexico, School of Medicine, Albuquerque, NM, USA.
  • Department of Otolaryngology, University of Kansas Medical Center, Kansas City, KS, USA.
  • Carbone Cancer Center, University of Wisconsin Madison, WI, USA.
  • Department of Pathology, University of Kansas Medical Center, Kansas City, KS, USA.
  • Department of Chemistry, University of Kansas, Topeka, KS, USA.

Förderung

  • NIGMS NIH HHS
  • NCI NIH HHS
  • NIBIB NIH HHS
  • The University of Kansas Cancer Center
  • National Institute of General Medical Sciences
  • National Institutes of Health National Cancer Institute
  • The University of Kansas Medical Center

Zitieren

APA

Morgan, D., Okwuone, D. D., Berggren, K. L., Arnold, L., Schmidt, A., Spiess, C., Smith, H., Yada, R., Hendrikse, N., Madan, R., Shrock, D., Lominska, C., Hu, M., Witek, M., Soper, S., Lin, Y., Gao, H., McCance, D. J., Thomas, S. M., …, & Gan, G. N. (2025). MK2 promotes p16 negative head and neck cancer migration, invasion, and metastasis. Cancer Letters, 622, 217690. https://doi.org/10.1016/j.canlet.2025.217690

Vancouver

Morgan D, Okwuone DD, Berggren KL, Arnold L, Schmidt A, Spiess C, et al. MK2 promotes p16 negative head and neck cancer migration, invasion, and metastasis. Cancer Letters. 2025;622:217690. doi:10.1016/j.canlet.2025.217690

BibTeX
@article{Morgan2025,
  author = {Morgan, Deri and Okwuone, Dakota Dd and Berggren, Kiersten L and Arnold, Levi and Schmidt, Alyssa and Spiess, Colby and Smith, Hannah and Yada, Ravi and Hendrikse, Nathan and Madan, Rashna and Shrock, Devin and Lominska, Chris and Hu, Mengjia and Witek, Malgorzata and Soper, Steven and Lin, Yuting and Gao, Hao and McCance, Dennis J and Thomas, Sufi M and Beebe, David and Kerr, Sheena C and Gan, Gregory N},
  title = {MK2 promotes p16 negative head and neck cancer migration, invasion, and metastasis},
  journal = {Cancer Letters},
  year = {2025},
  volume = {622},
  pages = {217690},
  doi = {10.1016/j.canlet.2025.217690}
}
Kostenlos starten →